AAAAAA

   
Results: 1-12 |
Results: 12
A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia
Authors: Talley, NJ Van Zanten, SV Saez, LR Dukes, G Perschy, T Heath, M Kleoudis, C Mangel, AW
Citation: Nj. Talley et al., A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia, ALIM PHARM, 15(4), 2001, pp. 525-537
Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome
Authors: Watson, ME Lacey, L Kong, S Northcutt, AR McSorley, D Hahn, B Mangel, AW
Citation: Me. Watson et al., Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome, AM J GASTRO, 96(2), 2001, pp. 455-459
Mice lacking the dopamine transporter display altered regulation of distalcolonic motility
Authors: Walker, JKL Gainetdinov, RR Mangel, AW Caron, MG Shetzline, MA
Citation: Jkl. Walker et al., Mice lacking the dopamine transporter display altered regulation of distalcolonic motility, AM J P-GAST, 279(2), 2000, pp. G311-G318
Alosetron for irritable bowel syndrome - Reply
Authors: Mangel, AW
Citation: Aw. Mangel, Alosetron for irritable bowel syndrome - Reply, LANCET, 356(9246), 2000, pp. 2009-2010
Alosetron in irritable bowel syndrome - Reply
Authors: Mangel, AW
Citation: Aw. Mangel, Alosetron in irritable bowel syndrome - Reply, LANCET, 356(9224), 2000, pp. 164-165
Efficacy and safety of alosetron in women with irritable bowel syndrome: arandomised, placebo-controlled trial
Authors: Camilleri, M Northcutt, AR Kong, S Dukes, GE McSorley, D Mangel, AW
Citation: M. Camilleri et al., Efficacy and safety of alosetron in women with irritable bowel syndrome: arandomised, placebo-controlled trial, LANCET, 355(9209), 2000, pp. 1035-1040
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist
Authors: Camilleri, M Mayer, EA Drossman, DA Heath, A Dukes, GE McSorley, D Kong, S Mangel, AW Northcutt, AR
Citation: M. Camilleri et al., Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist, ALIM PHARM, 13(9), 1999, pp. 1149-1159
Review article: evaluation of drugs in experimental gut distension models
Authors: Pappas, TN Mangel, AW Lawson, C
Citation: Tn. Pappas et al., Review article: evaluation of drugs in experimental gut distension models, ALIM PHARM, 13, 1999, pp. 54-56
Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients
Authors: Mangel, AW Northcutt, AR
Citation: Aw. Mangel et Ar. Northcutt, Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients, ALIM PHARM, 13, 1999, pp. 77-82
Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist
Authors: Miura, M Lawson, C Clary, EM Mangel, AW Pappas, TN
Citation: M. Miura et al., Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist, DIG DIS SCI, 44(1), 1999, pp. 20-24
Activation of calcium channels by cAMP in STC-1 cells is dependent upon Ca2+ calmodulin-dependent protein kinase II
Authors: Basavappa, S Mangel, AW Scott, L Liddle, RA
Citation: S. Basavappa et al., Activation of calcium channels by cAMP in STC-1 cells is dependent upon Ca2+ calmodulin-dependent protein kinase II, BIOC BIOP R, 254(3), 1999, pp. 699-702
Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome Criteria
Authors: Hamm, LR Sorrells, SC Harding, JP Northcutt, AR Heath, AT Kapke, GF Hunt, CM Mangel, AW
Citation: Lr. Hamm et al., Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome Criteria, AM J GASTRO, 94(5), 1999, pp. 1279-1282
Risultati: 1-12 |